Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas

Cancer

Volumn 118, Issue 13, 2012, Pages 3330-3336

  Italiano, Antoine ^a,b   Cioffi, Angela ^b,c   Penel, Nicolas ^d   Levra, Matteo Giaj ^c   Delcambre, Corinne ^e   Kalbacher, Elsa ^f   Chevreau, Christine ^g   Bertucci, François ^h   Isambert, Nicolas ⁱ   Blay, Jean Yves ^j   Bui, Binh ^a   Antonescu, Cristina ^b   D'Adamo, David R ^b   Maki, Robert G ^k   Keohan, Mary Louise ^b  

^a INSTITUT BERGONIÉ   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

^j CENTRE LÉON BÉRARD   (France)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Angiosarcoma; Chemotherapy; Doxorubicin; Paclitaxel; Prognosis

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTATIC ANGIOSARCOMA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMANGIOSARCOMA; HUMANS; MALE; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84862509604     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26599     Document Type: Article

References (41)

1. Fletcher CDM, Unni KK, Mertens F,. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
2. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007; 18: 2030-2036. (Pubitemid 350286245)
3. Bramwell VH, Anderson D, Charette ML,; Sarcoma Disease Site Group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev. 2003; 3: CD003293.
4. McArthur G,. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol. 2004; 31: 30-36. (Pubitemid 38879420)
5. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28: 1772-1779.
6. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 3483-3489. (Pubitemid 32730085)
7. Pautier P, Bui Nguyen B, Penel N, et al. Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS) [abstract]. J Clin Oncol. 2009; 27 (15 suppl):Abstract 10527.
8. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602. (Pubitemid 46995623)
9. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010; 21: 1135-1137.
10. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010; 28: 835-840.
11. Perez-Ruiz E, Ribelles N, Sanchez-Muñoz A, Roman A, Marquez A,. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol. 2009; 48: 1078-1079.
12. Castilla E, Pascual I, Roncalés F, Aguirre E, Del Río A,. Transient response of cardiac angiosarcoma to paclitaxel. Eur J Cancer Care (Engl). 2010; 19: 699-700.
13. Gambini D, Visintin R, Locatelli E, et al. Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Tumori. 2009; 95: 828-831.
14. Vakkalanka B, Milhem M,. Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. Clin Med Insights Oncol. 2010; 4: 107-110.
15. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999; 86: 2034-2037.
16. Skubitz KM, Haddad PA,. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005; 104: 361-366. (Pubitemid 40993264)
17. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG,. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005; 11: 241-247. (Pubitemid 44698813)
18. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008; 44: 2433-2436.
19. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008; 26: 5269-5274.
20. Casali PG, Blay JY,; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v198-v203.
21. Weiss SW, Goldblum JR,. Malignant vascular tumors. In:, Weiss SW, Goldblum JR, eds. Enzinger and Weiss's Soft Tissue Tumors. 5th ed. Philadelphia, PA: Mosby Elsevier; 2008: 703-732.
22. Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR,. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011; 50: 25-33.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
24. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000; 18: 2081-2086. (Pubitemid 30324361)
25. Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL,. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol. 2003; 23: 7256-7270. (Pubitemid 37211006)
26. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992; 69: 119-128.
27. Albihn A, Lovén J, Ohlsson J, Osorio LM, Henriksson M,. c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases,and PKCdelta signaling. J Cell Biochem. 2006; 98: 1597-1614. (Pubitemid 44141863)
28. Adachi S, Obaya AJ, Han Z, Ramos-Desimone N, Wyche JH, Sedivy JM,. c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol Cell Biol. 2001; 21: 4929-4937. (Pubitemid 32656391)
29. Grassilli E, Ballabeni A, Maellaro E, Del Bello B, Helin K,. Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem. 2004; 279: 21318-21326. (Pubitemid 38656539)
30. Bucci B, D'Agnano I, Amendola D, et al. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res. 2005; 11: 2756-2767. (Pubitemid 40569478)
31. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G,. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol. 2001; 60: 174-182. (Pubitemid 32595245)
32. Leonetti C, Biroccio A, Candiloro A, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res. 1999; 5: 2588-2595. (Pubitemid 29437346)
33. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009; 69: 7175-7179.
34. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999; 17: 150-157. (Pubitemid 29022388)
35. Penel N, Glabbeke MV, Mathoulin-Pelissier S, et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer. 2011; 104: 1544-1550.
36. Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011; 22: 257-267.
37. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep. 1980; 64: 47-51. (Pubitemid 10125452)
38. Penel N, Italiano A, Ray-Coquard I, et al. on behalf of the French Sarcoma Group (GSF/GETO). Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome [published online ahead of print May 12, 2011]. Ann Oncol. doi:10.1093/annonc/ mdr138.
39. Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network [published online ahead of print April 4, 2011]. Ann Oncol. doi:10.1093/annonc/mdr066.
40. Agulnik M, Okuno SH, Von Mehren M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma [abstract]. J Clin Oncol. 2009; 27:(15 suppl):Abstract 10522.
41. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133-3140.